Results for this period
First quarter1 January 2026–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
No direct factors behind the narrower operating loss have been explained. The company recorded ¥3.044 million in interest income and ¥9.443 million in foreign exchange gains as non-operating income, and ¥2.986 million in interest expense and ¥2.158 million in stock issuance costs as non-operating expenses.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥3 million |
| Operating profit | ¥-420 million |
| Ordinary income | ¥-413 million |
| Profit attributable to owners of the parent | ¥-414 million |
| Net income per share | ¥(14.16) |
| Equity ratio | End of the current fiscal period 79.2 / End of previous period 87.6 |
| Total assets | ¥4,528 million |
| Net assets | ¥3,593 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00（0.0%） |
| Depreciation and amortization | ¥13 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 29,302,700 Shares |
| Treasury Shares at Period-End | 17,702 Shares |
| Factors Behind Changes in Business Performance | No direct factors behind the narrower operating loss have been explained. The company recorded ¥3.044 million in interest income and ¥9.443 million in foreign exchange gains as non-operating income, and ¥2.986 million in interest expense and ¥2.158 million in stock issuance costs as non-operating expenses. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has not explained the direct factors behind the narrower operating loss. It explained that forecasting full-year results is difficult because performance may fluctuate significantly depending on whether milestone revenue is received, product sales revenue from OBP-301, drug pricing and market development, the terms of overseas alliance agreements, and other factors that remain uncertain.